Chilean Pharma: Exploring Beyond Copper - Pharmaceutical Executive

ADVERTISEMENT

Chilean Pharma: Exploring Beyond Copper


Pharmaceutical Executive



Rene Delsin, General Manager of Roche
This agility is exemplified by Zerpa's decision to "create a sales structure with representatives specially trained to support our institutional clients, such as hospitals, patient programs, and CENABAST. The Chilean government has been modernizing the public healthcare system over the years, and we must ensure that our services take these reforms into account so that patients have wider access to our products. I am confident that this will also make our products and services more competitive—vis--vis low-cost generics." Beyond their sales strategies, Pfizer has seized the advantages of Chile's updated regulatory environment and rich scientific community for clinical research and has already completed 49 of its trials in the country. Even more impressive is Sanofi-Aventis' dedicated clinical research center in Santiago that in 2009 invested US$6.3 million into its operations.


Katia Trusich, General Manager of Genzyme
Indeed Mauricio Rosas, managing director of Merck's pharmaceutical division, also believes that the current environment is promising for innovators. "Even though we are facing tough competition from generics and private labels, we are still top-of-mind for our clients. Our sales force is exceptional because it has managed to build strong relationships with the practitioners," he says. Their sales prowess is so impressive that they have been asked by BMS, AstraZeneca, and Novartis to commercialize some of their products in the Chilean market. "If we include the BMS products that we distribute, then Chile is actually the country with the highest market share for Merck in Latin America. Moreover, Chile represents 5% of the Latin American operations in terms of sales for the group, which is a very good figure taking into consideration that the Chilean pharmaceutical market in general is only 3% of Latin American sales," details Rosas. Riding on the company's local excellence, he foresees that "in the next few years the market is expected to grow at 6% and we plan to maintain our growth rate at the actual level of 12%." With such figures it is evident that global innovators have learned the ways of the Chilean market and are taking advantage of the opportunities being created by the optimized healthcare sector. MSD general manager Henrik Secher expresses this best by saying: "I wouldn't say that we have completely resolved these issues in Chile, but we have been dealing with them for a lot more time here and this means that we have greater chances to fight back and to leverage our position."


ADVERTISEMENT

blog comments powered by Disqus

Source: Pharmaceutical Executive,
Click here